Cell Line Development Services Market to Double, Reaching USD 12,957.8 Million by 2033 at a 7.4% of CAGR

Cell Line Development Services Market

The demand for cell line development services market is set to surge, with an anticipated valuation of USD 6,365.2 million in 2023, projected to grow at a robust compound annual growth rate (CAGR) of 7.4% from 2023 to 2033. According to Future Market Insights (FMI), the market is expected to reach USD 12,957.8 million by the end of 2033.

This substantial growth is driven by ongoing research advancements and technological innovations in the biotechnology sector. Over the period from 2018 to 2022, the market demonstrated a solid CAGR of 6.5%, laying a strong foundation for future expansion.

Cell line development services are pivotal in biopharmaceutical research and drug development, facilitating the production of consistent and reliable cell lines for various applications including vaccine development, monoclonal antibody production, and gene therapy.

Get your PDF Sample Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-4339

The biopharmaceutical sector relies on cell line development services to produce vaccines and biologics for a range of therapeutic uses. These services include, among other things, cell line engineering, cell banking, and cell line characterization—all crucial procedures for the creation and production of novel medications.

The market for cell line creation services is expected to grow, and several important factors will make this possible. The significance of efficiency and scalability in cell line development solutions has grown due to the swift progress of biotechnology and the growing demand for biopharmaceuticals. Furthermore, the market’s growth is being supported by the increasing demand for biologic pharmaceuticals due to the increased emphasis on tailored care as well as the rise in infectious and chronic illnesses.

The increasing frequency of neurological disorders and cancer, coupled with the dearth of effective treatment options for these conditions, have created a need for more advanced and efficient treatment pathways. Companies and government agencies are investing funds in research and development initiatives and focusing more on the generation of cell lines in order to identify novel biological pathways for the synthesis of cutting-edge drugs. The increased research and development spending on biosimilars made by departing biopharmaceutical corporations would be advantageous to the cell line development industry.

Market Competition:

Lonza, MabPlex Inc., Thermo Fisher Scientific, Inc., Solentim Ltd., Sigma-Aldrich Corporation, Selexis, Corning, Inc., Wuxi App Tec, Inc., and Sartorius AG are a few of the major players in the worldwide cell line development services market.

The market is extremely competitive as a result of the large number of participants. Regional players are present in key development regions, especially Asia Pacific, but global players like Lonza, MabPlex Inc., Thermo Fisher Scientific, Inc., and Solentim Ltd. still hold a significant share of the market.

• In May 2022 – ALSA Ventures, and Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries, announced today a framework collaboration agreement to help ALSA’s portfolio of pre-clinical and early clinical biotechs develop and manufacture biologics and small molecule drug candidates.
• In March 2021 – Pionyr Immunotherupatics collaborated with Lonza to support their oncology product development. Lonza will help Pionyr with cell line development and offer optimal yield and throughput.
• In June 2022 – WuXi Advanced Therapies and Wugen Inc., announced a partnership to produce Wugen’s WU-NK-101, a novel immunotherapy that harnesses the power of memory natural killer (NK) cells to treat cancers. WuXi ATU will provide manufacturing and testing services for WU-NK-101 to enable the delivery of this innovative cell therapy to cancer patients.

Customization Available:
https://www.futuremarketinsights.com/customization-available/REP-GB-4339

Key Companies Profiled:

• Lonza
• MabPlex Inc.
• Thermo Fisher Scientific, Inc.
• Solentim Ltd
• Sigma-Aldrich Corporation
• Selexis
• Corning, Inc
• Wuxi App Tec Inc.
• Sartorius AG

Key Segments Profiled in the Cell Line Development Services Industry Survey

By Product Type:

• Media and Reagents
• Equipment
• Others Cell Line Development Service Products

By Type:

• Primary Services
• Continuous Services
• Hybridomas Services
• Recombinant Cell Line Development Services

By Application:

• Bioproduction
• Diagnostics
• Vaccines
• Recombinant Protein Therapeutics
• Tissue Engineering & Regenerative Medicines
• Drug Discovery
• Toxicity Testing
• Pharmaceutical and Biotechnology Research

By Region:

• North America Market
• Latin America Market
• Europe Market
• Asia Pacific Market
• Middle East & Africa Market

In-Depth Market Analysis: Purchase Now to Access:
https://www.futuremarketinsights.com/checkout/4339

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube